ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,459.10
      1.11%
      US Tech 100
      18,514.00
      1.00%
      Dow Jones
      40,589.34
      1.64%
      Brent Oil
      79.745
      0.00%
      Bitcoin
      67,832.40
      -0.12%
      Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. Europe
      5. EU

      6. Argen X SE (ARGX) Quote

      Argen X SE

      Argen X SE (ARGX)

      argenx SE
      451.40
      7.70
      (1.74%)
      Closed July 27 11:30AM
      Delayed by 15 minutes

      Professional-Grade Tools, for Individual Investors.

      Premium

      Key stats and details

      Current Price
      451.40
      Bid
      442.30
      Ask
      455.50
      Volume
      110,103
      436.40 Day's Range 451.90
      271.00 52 Week Range 493.60
      Market Cap
      26.72B
      Previous Close
      443.70
      Open
      443.80
      Last Trade
      4
      @
      451.4
      Last Trade Time
      Financial Volume
      -
      VWAP
      -
      Average Volume (3m)
      65,992
      Shares Outstanding
      59,194,000
      Dividend Yield
      -
      PE Ratio
      -90.56
      Earnings Per Share (EPS)
      -4.98
      Revenue
      1.27B
      Net Profit
      -295.05M

      About Argen X SE

      Sector
      Coml Physical, Biologcl Resh
      Industry
      Coml Physical, Biologcl Resh
      Website
      www.argenx.com
      Headquarters
      Amsterdam, North Holland, Nld
      Founded
      1970
      Argen X SE is listed in the Coml Physical, Biologcl Resh sector of the Euronext with ticker ARGX. The last closing price for Argen X was 443.70 €. Over the last year, Argen X shares have traded in a share price range of 271.00 € to 493.60 €.

      Argen X currently has 59,194,000 shares outstanding. The market capitalization of Argen X is 26.26 € billion. Argen X has a price to earnings ratio (PE ratio) of -90.56.

      ARGX Latest News

      More News

      argenx Reports Half Year 2024 Financial Results and Provides Second Quarter Business Update

      $478 million in second quarter global net product sales First CIDP patients treated with VYVGART® Hytrulo following June 21st FDA approval On track to begin four additional registrational...

      July 25 2024
      GlobeNewswire Inc.

      argenx to Report Half Year 2024 Financial Results and Second Quarter Business Update on July 25, 2024

      July 18, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases...

      July 18 2024
      GlobeNewswire Inc.

      argenx and Zai Lab Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China

      First and only NMPA-approved subcutaneous injectable FcRn blocker for gMG patients in China Consistent clinical benefit and safety profile of efgartigimod SC compared to IV demonstrated in...

      July 16 2024
      GlobeNewswire Inc.

      argenx Highlights Breadth of Autoimmune Pipeline with New Multifocal Motor Neuropathy Data at 2024 Peripheral Nerve Society Annual Meeting

      ARDA study data show potential for empasiprubart to drive functional improvement and reduced risk of relapse for multifocal motor neuropathy (MMN) patients ADHERE+ data show durability of...

      June 25 2024
      GlobeNewswire Inc.

      argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy

      VYVGART® Hytrulo is first and only neonatal Fc receptor (FcRn) blocker approved to treat chronic inflammatory demyelinating polyneuropathy (CIDP) First novel, precision mechanism of action in...

      June 21 2024
      GlobeNewswire Inc.

      argenx to unveil its ‘Vision 2030: Taking Breakthrough Science to 50,000 Patients’ during its Upcoming R&D Day on July 16, 2024

      R&D Day presentations to include recent Phase 2 datasets in Sjogren’s disease (efgartigimod) and multifocal motor neuropathy (empasiprubart) that support advancement to Phase 3 development...

      June 17 2024
      GlobeNewswire Inc.

      argenx to Present at Goldman Sachs 45th Annual Global Healthcare Conference

      June 4, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases...

      June 04 2024
      GlobeNewswire Inc.

      argenx Reports First Quarter 2024 Financial Results and Provides Business Update

      $398 million in first quarter global net product sales FDA review ongoing for CIDP sBLA with PDUFA target action date of June 21, 2024 On track to submit filing for pre-filled syringe (PFS) in...

      May 09 2024
      GlobeNewswire Inc.

      argenx announces results of Annual General Meeting of Shareholders

      May 7, 2024 – 5:30pm ET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe...

      May 07 2024
      GlobeNewswire Inc.

      argenx to Present at BofA Securities 2024 Health Care Conference

      May 7, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases...

      May 07 2024
      GlobeNewswire Inc.
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      120.44.73317865429431466.4423.294005435.02788396DE
      434.48.24940047962417466.4398.261140422.8677342DE
      1287.424.010989011364466.4323.465992382.29401393DE
      26100.228.5307517084351.2466.4322.562277369.46118945DE
      52-25.6-5.36687631027477493.627160983395.29179092DE
      156183.568.4957073535267.9494.1224.165384348.05514714DE
      260324.4255.433070866127494.193.0579636263.38080604DE

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      WINTWindtree Therapeutics Inc
      $ 8.24
      (150.46%)
      		48.57M
      BFIBurgerFi International Inc
      $ 0.4206
      (97.37%)
      		313.59M
      NBSTWNewbury Street Acquisition Corporation
      $ 0.1349
      (92.71%)
      		122.1k
      YIBOPlanet Image International Ltd
      $ 2.915
      (53.43%)
      		260.07k
      CREVCarbon Revolution Public Ltd
      $ 9.00
      (45.87%)
      		8.06M
      NMHINatures Miracle Holding Inc
      $ 0.2035
      (-48.06%)
      		7.69M
      TANHTantech Holdings Ltd
      $ 0.2585
      (-47.23%)
      		6.75M
      DXCMDexCom Inc
      $ 64.00
      (-40.66%)
      		53.92M
      PSIGPS International Group Ltd
      $ 1.42
      (-31.40%)
      		716.26k
      POAIPredictive Oncology Inc
      $ 1.36
      (-27.27%)
      		6.02M
      SLNASelina Hospitality PLC
      $ 0.0305
      (-18.88%)
      		408.61M
      BFIBurgerFi International Inc
      $ 0.4206
      (97.37%)
      		313.59M
      NVDANVIDIA Corporation
      $ 113.06
      (0.69%)
      		293.33M
      SQQQProShares UltraPro Short QQQ
      $ 9.10
      (-2.88%)
      		176.49M
      SGMOSangamo Therapeutics Inc
      $ 0.8612
      (28.15%)
      		123.71M

      Discussion

      View Full Feed
      lakers17 lakers17 5 minutes ago
      It’s a historic week for the cryptocurrency markets with spot ether exchange-traded funds making their debut.

      Franklin Templeton is one of the nine spot ether ETF applicants which got approval Tuesday from the Securities and Exchange commission.

      The firm is behind the F
      The Night Stalker The Night Stalker 5 minutes ago
      STAL big history of runs
      STAL
      Acme Investments Acme Investments 7 minutes ago
      Well let's throw Tim Sykes into the conversation while we're at it!! Sell courses get rich, actually trade 99% fail!!
      HIRU
      BDEZ BDEZ 8 minutes ago
      The ‘sloped roof’ in Butler, PA is flat

      https://x.com/bennyjohnson/status/1816953010984984724
      BDEZ BDEZ 8 minutes ago
      The ‘sloped roof’ in Butler, PA is flat

      https://x.com/bennyjohnson/status/1816953010984984724
      tradeherpete tradeherpete 9 minutes ago
      I'll be checking the Anavex website around 8 or 9am on Sunday, maybe they'll have something interesting to say?
      AVXL
      DKLN DKLN 11 minutes ago
      Keep complaining about the OTC when the "company"/management team that you praise/defend produces zippo revenue for investors in 10 consecutive quarterly reports. How many times did a few clueless people on this Board mention "merger" and "sales" in the past month? Those clueless people should stop
      MCIC
      BDEZ BDEZ 12 minutes ago
      $8.2 billion in aid for Ukraine being misplaced

      https://x.com/MarioNawfal/status/1816840664983687203
      vdog1776 vdog1776 14 minutes ago
      Good I like a downward trend I might get my 30 extra million shares if people are so stupid!!! 15 million of those would be in my Roth so please let’s dip one more time, before we explode!!!

      We are in a holding pattern for now for a couple of reasons.

      1. The OTC is not
      VXIT
      johnydollar johnydollar 14 minutes ago
      How would one know the benefits of NOLs........

      Don't you think one has to ran a business to understand them.......

      Or at least understand it's not a crime for a business to file a loss.......

      Employees don't file NOLs.......

      So yeah, $DBMM
      DBMM
      surfer44 surfer44 14 minutes ago
      I certainly don't feel represented. :-(

      What is the approval rating for Congress in 2024?

      The most recent polling data from May 2024 puts the approval rating of the United States Congress at 13 percent, reflecting a slight decrease from April. The approval rating has re
      BDEZ BDEZ 15 minutes ago
      Kamala’s role in the disastrous Afghanistan withdrawal.

      https://x.com/libsoftiktok/status/1816933500240777393
      Zorax Zorax 15 minutes ago
      Part of my point is the fashion designer or show designer herself isn't falling off 12 stilettos or 30 foot springy thin poles.
      It's for the art, but sometimes I wonder about the egos.
      SloGin SloGin 16 minutes ago
      Thats sad! Sorry for your loss.

      Hang tight man!

      We got the HIRU co the new control block owners (wealthy backers) + M&A firm all in our corner fighting tooth and nail.

      If its any consolation HIRU was 300 mill shorted now about 100 mill. So 200 mill cove
      HIRU
      janice shell janice shell 21 minutes ago
      Oh yes! I always knew that!! I'm so glad you realize it, too!!
      boobb2 boobb2 21 minutes ago
      Well 3rd quarter filing is due by Nov 15th
      MCIC
      CanItBThisEZ2Make CanItBThisEZ2Make 23 minutes ago
      The results for the whole day was --->
      Buy: 11,487,209
      Neutral: 3,483,765
      Sell: 15,407,513
      MAXN
      boston745 boston745 24 minutes ago
      Stating a buy out as a fact is securities fraud
      Oh TA, im not the first to state that. I'm just the one that has collected evidence that strongly supports the claim as well as show the partnership between the companies. Not to mention show that Sintx CEO came from Zimmer to help Sintx develop
      SINT

      Your Recent History

      EU
      ARGX
      Argen X
      Delayed Upgrade Clock